Floatz logo

Tislelizumab

Lenvatinib

Zhejiang Cancer Hospitalmonoclonal_antibodyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Lenvatinib cohort.

Asset / SponsorPhaseRating
LENVATINIB
Sun Yat-sen University
Phase 2BB
Theprubicin
Sun Yat-sen University
Phase 2B
Ethiodized Oil
Sun Yat-sen University
Phase 2B
Pembrolizumab
National Taiwan University Hospital
Phase 2B
Cyclophosphamide
Yale University
Phase 2CCC

View all 14 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →